MindMap Gallery Amgen Company History

Amgen Company History

This timeline chronicles the remarkable journey of Amgen, a leader in biotechnology, from its founding in 1980 to its current status as a diversified powerhouse. Amgen was founded in 1980 in Thousand Oaks, California. The company established foundational biologics manufacturing in the 1980s, developing expertise in recombinant DNA technology. Key breakthroughs came in the 1990s with the approval of EPOGEN (epoetin alfa, 1989) for anemia and NEUPOGEN (filgrastim, 1991) for neutropenia. These blockbuster products established Amgen as a biotech leader. The 2000s saw expansion into oncology, inflammation, and bone health. Amgen launched Enbrel (etanercept, 2002 acquisition of Immunex) for rheumatoid arthritis, Sensipar (cinacalcet) for hyperparathyroidism, and Prolia (denosumab) for osteoporosis. The 2010s marked expansion into biosimilars (ABP 215, ABP 798) and rare diseases (acquiring Onyx Pharmaceuticals – Kyprolis for multiple myeloma). Strategic acquisitions reinforced Amgen’s leadership: Immunex (2002, Enbrel), Onyx (2013, Kyprolis), Horizon Therapeutics (2023, rare disease drugs: Tepezza, Krystexxa, Uplizna). These added immunology, inflammation, and rare disease assets. Today, Amgen continues its commitment to innovation (bispecifics, gene therapy) and evidence generation (real-world studies, clinical trials). Amgen’s diversified portfolio (oncology, inflammation, cardiovascular, rare disease) ensures resilience in the rapidly evolving biotech landscape.

Edited at 2026-03-25 15:02:55
PlotWizard
PlotWizard

Amgen Company History

PlotWizard
PlotWizard
  • Recommended to you
  • Outline